Marietta Wealth Management LLC Sells 80 Shares of Eli Lilly and Company (NYSE:LLY)

Marietta Wealth Management LLC reduced its position in Eli Lilly and Company (NYSE:LLY) by 0.6% during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 12,824 shares of the company’s stock after selling 80 shares during the period. Eli Lilly and Company makes up 1.7% of Marietta Wealth Management LLC’s investment portfolio, making the stock its 16th largest holding. Marietta Wealth Management LLC’s holdings in Eli Lilly and Company were worth $11,361,000 at the end of the most recent quarter.

Several other hedge funds have also bought and sold shares of the business. Lynx Investment Advisory purchased a new position in shares of Eli Lilly and Company during the second quarter valued at approximately $32,000. LGT Financial Advisors LLC bought a new position in Eli Lilly and Company during the 2nd quarter valued at $36,000. Cedar Mountain Advisors LLC boosted its holdings in Eli Lilly and Company by 53.3% during the 3rd quarter. Cedar Mountain Advisors LLC now owns 46 shares of the company’s stock worth $41,000 after acquiring an additional 16 shares during the last quarter. Morton Brown Family Wealth LLC grew its stake in shares of Eli Lilly and Company by 45.5% in the 2nd quarter. Morton Brown Family Wealth LLC now owns 48 shares of the company’s stock worth $41,000 after acquiring an additional 15 shares in the last quarter. Finally, Unique Wealth Strategies LLC purchased a new stake in shares of Eli Lilly and Company in the second quarter valued at about $45,000. Institutional investors and hedge funds own 82.53% of the company’s stock.

Eli Lilly and Company Stock Performance

Shares of LLY opened at $902.96 on Thursday. Eli Lilly and Company has a 12-month low of $547.61 and a 12-month high of $972.53. The company has a current ratio of 1.11, a quick ratio of 0.87 and a debt-to-equity ratio of 1.74. The company has a market cap of $858.18 billion, a PE ratio of 132.98, a price-to-earnings-growth ratio of 2.79 and a beta of 0.42. The stock has a 50-day moving average price of $921.12 and a 200-day moving average price of $860.74.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings data on Thursday, August 8th. The company reported $3.92 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.64 by $1.28. Eli Lilly and Company had a net margin of 18.86% and a return on equity of 67.52%. The company had revenue of $11.30 billion during the quarter, compared to the consensus estimate of $9.83 billion. As a group, equities analysts forecast that Eli Lilly and Company will post 16.49 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of equities research analysts have issued reports on the stock. JPMorgan Chase & Co. upped their price objective on shares of Eli Lilly and Company from $1,050.00 to $1,100.00 and gave the stock an “overweight” rating in a research report on Friday, September 13th. Berenberg Bank upped their target price on Eli Lilly and Company from $1,000.00 to $1,050.00 and gave the company a “buy” rating in a report on Wednesday, August 14th. Guggenheim lifted their price target on Eli Lilly and Company from $884.00 to $1,030.00 and gave the stock a “buy” rating in a report on Friday, August 16th. Truist Financial upped their price objective on Eli Lilly and Company from $1,000.00 to $1,033.00 and gave the company a “buy” rating in a research note on Thursday, October 10th. Finally, Bank of America lifted their target price on Eli Lilly and Company from $1,000.00 to $1,125.00 and gave the stock a “buy” rating in a research note on Friday, August 9th. Three analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company’s stock. Based on data from MarketBeat, Eli Lilly and Company currently has an average rating of “Moderate Buy” and a consensus price target of $1,002.24.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.